Celera 'Expediting' Lung Cancer Dx Development Based on Promising Study Results

Based on the results of the study, the company has assembled a panel of six protein biomarkers with the ability to detect non-small cell lung cancer in patients with 94 percent sensitivity and 93 percent specificity. The company is hoping to launch the test by 2012.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.